Skip to content
Screener

aTyr Pharma ATYR Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue-
EPS-$0.14Beat by $0.04
EPS estimate-$0.18

Next report

Nov 5, 2026 (in 3 months)
Revenue estimate$2.5M
EPS estimate-$0.17

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$14.8M+6.5%
Net income-$14.0M+6.7%
EPS (diluted)-$0.14+17.6%

Balance sheet

See full
Cash & equivalents$10.7M-2.8%
Total debt$12.7M-8.4%
Total equity$67.5M-3.6%
Total assets$93.0M-4.0%

Cash flow

See full
Operating cash flow-$12.2M+7.1%
CapEx$31.0K+24.0%
Free cash flow-$12.2M+7.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$76.73M-74.7%
Enterprise value$78.65M-74.3%
P/S403.9×-889×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-107.8%+58.8pp
Debt / equity0.2×0.0×
Current ratio5.3×-0.2×

FAQ

When did aTyr Pharma report Q4 2025 earnings?
aTyr Pharma (ATYR) reported Q4 2025 earnings on March 5, 2026 before market open.
What were aTyr Pharma's Q4 2025 revenue and EPS?
aTyr Pharma reported revenue of - and eps of $-0.14 for Q4 2025.
Did aTyr Pharma beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.18 by $0.04.
How did aTyr Pharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 22.2% from $-0.18.
Where can I find aTyr Pharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001339970-26-000006) and the 10-K periodic report (0001339970-26-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.